In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Settles Foreign Bribery Charges, Wins Deferred Prosecution For Helping Government

This article was originally published in PharmAsia News

Executive Summary

Pfizer reaches separate settlements with U.S. DoJ and SEC to resolve charges its subsidiaries bribed Chinese, Russian and other foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ.

You may also be interested in...

DoJ Bull’s Eye: Off-Label Promotion, Formulary Placements, FCPA Violations Remain Targets

A Pfizer attorney says government saber rattling over individual liability does not mean there will be a spike in individual prosecutions; Pfizer’s cooperation with the government helped it avoid criminal resolution in a Foreign Corrupt Practices Act settlement.

J&J Takes The Lead In Settling SEC/DoJ Foreign Corrupt Practices Act Probe

Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act

US FDA Puts Spotlight On Alkermes' Violative Vivitrol Ad

The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts